



**FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS  
AGENCE NATIONALE DU MEDICAMENT VETERINAIRE**

8 rue Claude Bourgelat –  
Parc d'activités de la grande Marche –  
Javené – CS 70611 –  
35306 FOUGERES

**DECENTRALISED PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT  
FOR A VETERINARY MEDICINAL PRODUCT**

**Dermipred 20 mg tablets for dogs  
Dermipred Vet 20 mg tablets for dogs (DK, FI, NO, SE)  
Prednisolone Ceva 20 mg tablets for dogs (FR)  
Dermipred, 20 mg tablets for dogs (EE, LT, LV)**

**DATE : JUNE 2018**

## **MODULE 1**

### **PRODUCT SUMMARY**

EU Procedure number	FR/V/0301/003/DC
Name, strength and pharmaceutical form	Dermipred/Prednisolone 20 mg Tablet
Applicant	CEVA SANTE ANIMALE 10 AVENUE DE LA BALLASTIERE 33500 LIBOURNE
Active substance(s)	Prednisolone
ATC Vetcode	QH02AB06
Target species	Dogs
Indication for use	For the symptomatic treatment or as adjunct treatment of inflammatory and immune-mediated dermatitis in dogs

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the website <http://www.anmv.anses.fr/>

## **MODULE 3**

### **PUBLIC ASSESSMENT REPORT**

Legal basis of original application	Hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	29/06/2016
Concerned Member States for original procedure	AT, BE, BG, CZ, DE, DK, ES, FI, IE, IT, LU, NL, NO, PL, PT, SE, SK, UK,
Concerned Member States for repeat use procedure (2 <sup>nd</sup> wave)	EE, HU, RO, LV, LT

#### **I. SCIENTIFIC OVERVIEW**

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; adverse reactions observed are indicated in the SPC.

The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

#### **II. QUALITY ASPECTS**

##### **A. Composition**

The product contains prednisolone 20 mg/tablet and the following excipients yeast, pig liver powder, silica, colloidal anhydrous, glycerol distearate and cellulose, microcrystalline.

The packaging of the finished product is as described on the SPC. The particulars of the containers and controls performed are provided and conform to the regulation.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

**B. Method of Preparation of the Product**

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

**C. Control of Starting Materials**

The active substance is prednisolone, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

**D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

Scientific data and certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

**E. Control on intermediate products**

Not applicable.

**F. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

**G. Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

**H. Genetically Modified Organisms**

Not applicable.

**J. Other Information**

Not applicable.

**III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)**

As this is a hybrid application according to Article 13(3), and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

The pharmacological and toxicological aspects of this product are identical to the reference product, Dermipred 10.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment.

**III.A Safety Testing**

**Pharmacological Studies**

The applicant referred to the reference product and did not provide data on mechanism of action of prednisolone.

The pharmacological aspects of this product are identical to the reference product.

**Toxicological Studies**

Since this application is made in accordance with Article 13(3) of Council Directive 2001/82/EC amended by Council Directive 2004/28/EC, no data from toxicological studies are required.

The toxicological aspects of this product are the same as those of the reference product.

Excipients are commonly used in oral veterinary pharmaceuticals/human medicines.

### ***User Safety***

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that risk populations, as persons known to be hypersensitive to corticosteroids or to any of excipients of products, and pregnant women should not handle products.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

### ***Environmental Risk Assessment***

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required because:

<The veterinary medicinal product will only be used in non-food animals.>

## **IV. CLINICAL ASSESSMENT (EFFICACY)**

As this is a hybrid application according to Article 13, and bioequivalence with the reference product has been demonstrated, efficacy studies are not required.

### ***IV.A Pre-Clinical Studies***

#### ***Pharmacology***

The similarity of dissolution with the reference product has been demonstrated in a study conducted with Dermipred/Prednisolone 5 mg, Dermipred/Prednisolone 10 mg and Dermipred/Prednisolone 20 mg. As these tablets are homothetic and as the bioequivalence between Dermipred/Prednisolone 10 mg has been established with the reference product, Dermipred/Prednisolone 20 mg can be considered as bioequivalent to the reference product.

#### ***Tolerance in the Target Species of Animals***

Due to the nature of the application no tolerance studies were required.

The bioequivalence is established between the test product and the reference one, the toxicological profile of both products is expected to be similar in target species.

Post marketing information has also shown that the incidence of adverse reactions is low.

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

### ***IV.B Clinical Studies***

As bioequivalence with a reference product has been demonstrated, efficacy studies are not required.

## **V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.



## **MODULE 4**

### **POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website ([www.HEVRA.org](http://www.HEVRA.org)).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

#### **Repeat use procedure**

Following procedure FR/V/0259/001/E/001, the following CMS accepted to grant the product a marketing authorisation. No change was brought to the SPC.